Exact Sciences Corporation
Exact Sciences Corporation (EXAS) develops and commercialises non‑invasive cancer screening tests, best known for Cologuard, a stool‑based colorectal cancer screening product. Investors should know the company’s growth depends on test adoption, reimbursement from insurers and its ability to expand into other cancer diagnostics through product launches and acquisitions. Revenue has historically been driven by screening volumes, pricing and payer coverage; margins can improve as fixed costs scale but may be pressured by marketing and R&D investment. Key risks include regulatory and reimbursement uncertainty, competition from lab and diagnostic rivals, and execution challenges in commercial expansion and new test development. The stock can be volatile and is sensitive to changes in clinical data, guideline updates and policy decisions. With a market cap near $12bn, Exact Sciences may appeal to investors seeking exposure to diagnostic innovation, but it is not suitable for everyone — consider your risk tolerance and time horizon and seek independent advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Exact Sciences stock with a target price of $100.47, indicating limited growth.
Financial Health
Exact Sciences is performing well with strong revenue and profitability, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EXAS
Activist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketLiquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Screening growth potential
Colorectal screening adoption and expanded guidelines could drive volume, though uptake depends on reimbursement and patient behaviour, so outcomes can vary.
Expanding global reach
International roll‑out and partnerships may open new markets, but regulatory hurdles and local payer systems can slow progress and add uncertainty.
Pipeline and innovation
R&D and acquisitions aim to broaden cancer detection offerings; promising data can boost prospects, while negative results or delays present downside risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
